Best-in-class noninvasive detection1-4*  

Among USPSTF-recommended screening methods, the Cologuard® test delivers higher sensitivity than other noninvasive options, like the fecal immunochemical test (FIT). The Cologuard test delivers sensitivity and specificity in detecting advanced precancerous lesions, helping to identify colorectal cancer (CRC) early in eligible patients.1-5

Four healthcare providers having a discussion in a healthcare setting.
Peer-reviewed studies demonstrate the Cologuard test may result in improved outcomes and cost-effectiveness compared with FIT.6-8*  †
Cologuard Plus™ test data

Loading component...

Loading component...

Loading component...

Loading component...

Cologuard test data

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

Loading component...

High specificity in average-risk patients aged 45-499
In a separate study of 816 patients at average risk aged 45 to 49 years, the Cologuard test demonstrated 95.2% specificity in patients with nonadvanced adenomas, nonneoplastic findings, and negative results on colonoscopy.9#
Five people in the age range of 45-49 in a discussion in an outdoor setting.
Learn how incorporating the Cologuard test may increase your system's screening rates
Health system experiences with the Cologuard test
Discover how your Electronic Health Record (EHR) can enable optimized workflows